Long-term study data confirm the durable antitumor activity associated with the anti–PD-1 antibody pembrolizumab in patients with melanoma, according to study results presented at the ASCO Annual Meeting.
Conferences
Sub-stage specific surveillance imaging detects relapses in melanoma
CHICAGO — Disease sub-stage specific PET imaging effectively detected relapses in stage III melanoma, according to findings presented at the ASCO Annual Meeting.
Findings support wider excision margins in melanoma
A surgical excision margin of 3 cm yielded significantly improved disease-specific survival but not OS in a cohort of patients with high-risk melanoma, according to findings presented at the ASCO Annual Meeting.
No Need for Lymph Node Dissection in Certain Melanoma Patients
Surgically removing lymph nodes does not improve survival for certain patients with melanoma. The results from the large phase III randomized Dermatologic Cooperative Oncology Group Trial (abstract LBA9002) were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held May 29 to June 2 in Chicago.